Dáil Éireann Debate, Wednesday - 21 April 2021
2267. Deputy David Cullinane asked the Minister for Health if he is considering adding any pure cannabidiol product with trace tetrahydrocannabinol content to the medical cannabis access programme considering that no products on the programme currently are suitable for treating epilepsy; and if he will make a statement on the matter. [20344/21]
View answer2268. Deputy David Cullinane asked the Minister for Health if there are barriers to adding pure cannabidiol products to the medical cannabis access programme; and if he will make a statement on the matter. [20345/21]
View answerI propose to take Questions Nos. 2267 and 2268 together.
The objective of the Medical Cannabis Access Programme (MCAP) is to allow access to products containing a substance controlled under the Misuse of Drugs framework.
Pure CBD (containing no THC, a controlled substance) does not fall within the framework, and is therefore not eligible for inclusion in the MCAP.
